Composite including neural retina, retinal pigment epithelial cells, and hydrogel, and method for producing same

Patent metadata

Field	Value
Publication number	US-12533382-B2
Application number	US-202017605573-A
Country	US
Kind code	B2
Filing date	Apr 24, 2020
Priority date	Apr 26, 2019
Publication date	Jan 27, 2026
Grant date	Jan 27, 2026

Abstract

Provided is a composite comprising a neural retina, a retinal pigment epithelial cell sheet, and a hydrogel.

First claim

The invention claimed is:

1 . A composite comprising a neural retina, a retinal pigment epithelial cell sheet, and a hydrogel, wherein
the neural retina and the retinal pigment epithelial cell sheet are derived from a human pluripotent stem cell respectively; in the neural retina, a neural retinal layer including at least a photoreceptor layer is formed, wherein the photoreceptor layer comprises at least one or more cells selected from the group consisting of a photoreceptor cell, a photoreceptor precursor cell and a retinal precursor cell; a melting point of the hydrogel is from 20° C. to 40° C.; and the whole of the neural retina and the retinal pigment epithelial cell sheet is embedded in the hydrogel, tangent directions of the respective surfaces of the neural retina and the retinal pigment epithelial cell sheet are approximately parallel, an apical surface of the neural retina and an apical surface of the retinal pigment epithelial cell sheet face each other, and the neural retina and the retinal pigment epithelial cell sheet are separated by the hydrogel from each other without contact.

2 . The composite according to claim 1 , wherein a jelly strength of the hydrogel is from 1000 g to 2000 g.

3 . The composite according to claim 1 , wherein a concentration of the hydrogel is from 10% to 50% by weight.

4 . The composite according to claim 1 , wherein a pH of the hydrogel is from 6.5 to 7.5.

5 . The composite according to claim 1 , wherein the hydrogel has biodegradability.

6 . The composite according to claim 1 , wherein the hydrogel is a hydrogel of gelatin.

7 . The composite according to claim 6 , wherein the gelatin is alkali-treated and/or heat-treated gelatin.

8 . The composite according to claim 1 , wherein
the neural retina is a neural retina obtained from a cell aggregate obtained by differentiating a human pluripotent stem cell, the cell aggregate comprises at least a first epithelial tissue and a second epithelial tissue, wherein the first epithelial tissue contains a human neural retina, and the second epithelial tissue has continuity of a slope of a tangent line to a surface different from continuity of a slope of a tangent line to the surface of the first epithelial tissue, and contains a cell other than a retinal cell and/or a retinal pigment epithelial cell, and the neural retina contains a region on the first epithelial tissue most distant from the second epithelial tissue in the cell aggregate.

9 . A pharmaceutical composition comprising the composite according to claim 1 as an active ingredient.

10 . A therapeutic medication for a disease caused by a disorder of a retinal tissue or a damage of a retinal tissue, comprising the composite according to claim 1 .

11 . A composition for transplantation comprising the composite according to claim 1 .

12 . The composition for transplantation according to claim 11 , wherein the composition for transplantation is to be transplanted to the eye fundus or into the subretinal space in a patient.

13 . The composition for transplantation according to claim 12 , wherein the composition for transplantation is to be transplanted such that the composite is engrafted in a recipient patient in a condition in which the neural retina of the transplanted composite faces the neural retinal layer of the patient while the retinal pigment epithelial cell sheet of the transplanted composite faces the retinal pigment epithelial layer of the patient.

14 . A method for treating a disease caused by a disorder of a retinal tissue or a damage of a retinal tissue, comprising the steps of:
(1) transplanting the composite according to claim 1 to the eye fundus or into the subretinal space in a patient; and (2) engrafting the composite in vivo in the patient in a condition in which the neural retina of the transplanted composite faces the neural retinal layer of the patient while the retinal pigment epithelial cell sheet of the transplanted composite faces the retinal pigment epithelial layer of the patient.

Assignees

• Riken
• Racthera Co Ltd

Inventors

• Tanaka Yuji
• Mandai Michiko
• Takahashi Masayo
• YAMASAKI Suguru

Classifications

• A61P27/02 Primary

  Ophthalmic agents · CPC title

• A61L27/52

  Hydrogels or hydrocolloids · CPC title

• A61L27/383

  Nerve cells, e.g. dendritic cells, Schwann cells · CPC title

• A61L27/22

  Polypeptides or derivatives thereof {, e.g. degradation products} · CPC title

• A61K47/42

  Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34) · CPC title